Conflicts of interest have kept Lars Rebien Sørensen away from pharmaceutical boards – until now
Up until now, Lars Rebien Sørensen has refrained from taking on board roles at pharmaceutical companies due to the risk of conflicts of interest. Now, the chairman of the Novo Nordisk Foundation will be taking on the role of chairman of the board at Ferring, although he highlights one possible conflict of interest with Denmark's largest pharmaceutical giant.
BY ULRICH QUISTGAARD, TRANSLATED BY NIELSINE NIELSEN
As the future chairman of Ferring Pharmaceuticals, Lars Rebien Sørensen will soon be taking on his first board role within the pharmaceutical industry.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.